Alopecia Areata and Ritlecitinib: Unraveling Response Trajectories

May 2025 in “ Journal of the European Academy of Dermatology and Venereology ”

Julien Sénéschal

ritlecitinib JAK3/TEC family kinase inhibitor alopecia areata SALT score baricitinib JAK inhibitors

From the encyclopedia

autoimmune disorder causing patchy hair loss

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

Studysummary This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

research Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata

December 2024 in “Clinical and Experimental Dermatology”

In this study, researchers found that ritlecitinib, a JAK3/TEC inhibitor, significantly improves hair regrowth, quality of life, and psychological well-being in patients with severe alopecia areata who had inadequate or no response to baricitinib, a JAK1/2 inhibitor.

Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

September 2023 in “British Journal of Dermatology”

In this study, researchers identified subgroups of patients with severe alopecia areata treated with baricitinib who experienced early, gradual, or late hair regrowth, finding that response was influenced by baseline disease severity and duration of hair loss.

Major Improvement of Very Severe Alopecia Areata in Patients Treated With the Combination of Baricitinib and Low Doses of Corticosteroids: An Eight-Case Series

research Major Improvement of Very Severe Alopecia Areata in Patients Treated With the Combination of Baricitinib and Low Doses of Corticosteroids: An Eight-Case Series

July 2023 in “Clinical and Experimental Dermatology”

In this study, combining baricitinib and prednisone effectively achieved complete hair regrowth in seven out of eight women with very severe alopecia areata, contrasting with less effective results from each drug used alone.